# Role of AT1-receptor Blockers in Insulin-induced Vasodilation.

> **NCT00742066** · NA · UNKNOWN · sponsor: **Maastricht University Medical Center** · enrollment: 32 (estimated)

## Conditions studied

- Hypertension
- Insulin Resistance
- Microcirculation

## Interventions

- **DRUG:** Irbesartan
- **DRUG:** Felodipine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00742066
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-03
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2011-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742066, "Role of AT1-receptor Blockers in Insulin-induced Vasodilation.". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00742066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*